# Aadi Bioscience Inc. (AADI)

Source: https://www.quantisnow.com/company/AADI
Generated: 2026-11-18T05:54:32.273Z

- Ticker: AADI
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- Website: aadibio.com

## Latest AADI news and filings

- 2025-03-28 20:53 UTC [SEC Form S-8] [SEC Form S-8 filed by Aadi Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-aadi-bioscience-inc-5965208)
- 2025-03-26 12:21 UTC [SEC Form 8-K] [Aadi Bioscience Inc. filed SEC Form 8-K: Financial Statements and Exhibits](https://www.quantisnow.com/insight/aadi-bioscience-inc-filed-sec-form-8-k-financial-statements-and-5960507)
- 2025-03-18 20:38 UTC [SEC Form 8-K] [Aadi Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aadi-bioscience-inc-filed-sec-form-8-k-results-of-operations-5950167)
- 2025-03-18 13:29 UTC [SEC Form D] [SEC Form D filed by Aadi Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-d-filed-by-aadi-bioscience-inc-5949007)
- 2025-03-14 12:00 UTC [Earnings Date] [Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update](https://www.quantisnow.com/insight/aadi-bioscience-to-report-fourth-quarter-and-full-year-2024-results-5944360)
- 2025-03-11 23:22 UTC [SEC Form SCHEDULE 13G filed by Aadi Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-aadi-bioscience-inc-5939420)
- 2025-03-06 00:51 UTC [SEC Form 4] [Director Dalal Anupam was granted 1,561,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-dalal-anupam-was-granted-1561000-shares-sec-form-4-5929618)
- 2025-03-05 20:58 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Aadi Bioscience Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-aadi-bioscience-inc-5927807)
- 2025-03-05 00:24 UTC [SEC Form 4] [Director Castelein Caley was granted 1,666,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-castelein-caley-was-granted-1666000-shares-sec-form-4-5926068)
- 2025-03-04 23:14 UTC [SEC Form 4] [Director Zhao Baiteng was granted 1,250,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-zhao-baiteng-was-granted-1250000-shares-sec-form-4-5925612)
- 2025-03-04 23:11 UTC [SEC Form 4] [SEC Form 4 filed by Chief Scientific Officer Dornan David](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-scientific-officer-dornan-david-5925596)
- 2025-03-04 23:09 UTC [SEC Form 4] [Officer Ball Bryan converted options into 5,000 shares, sold $5,045 worth of shares (2,147 units at $2.35) and was granted 100,000 shares, increasing direct ownership by 103% to 202,853 units (SEC Form 4)](https://www.quantisnow.com/insight/officer-ball-bryan-converted-options-into-5000-shares-sold-5045-5925589)
- 2025-03-04 22:56 UTC [SEC Form 4] [SEC Form 4 filed by Director Aghazadeh Behzad](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-aghazadeh-behzad-5925469)
- 2025-03-04 21:16 UTC [SEC Form 8-K] [Aadi Bioscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure](https://www.quantisnow.com/insight/aadi-bioscience-inc-filed-sec-form-8-k-entry-into-a-5923714)
- 2025-03-04 21:05 UTC [Public Offering] [Aadi Bioscience Announces Closing of $100 Million PIPE Financing](https://www.quantisnow.com/insight/aadi-bioscience-announces-closing-of-100-million-pipe-financing-5923314)
- 2025-03-04 01:38 UTC [SEC Form 4] [CHIEF FINANCIAL OFFICER Giacobello Scott M. converted options into 6,750 shares and sold $6,594 worth of shares (2,806 units at $2.35), increasing direct ownership by 20% to 23,944 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-giacobello-scott-m-converted-options-into-6750-5921625)
- 2025-03-04 01:37 UTC [SEC Form 4] [CHIEF EXECUTIVE OFFICER Lennon David James converted options into 16,250 shares and sold $13,372 worth of shares (5,690 units at $2.35), increasing direct ownership by 46% to 33,429 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-lennon-david-james-converted-options-into-16250-5921622)
- 2025-03-03 13:00 UTC [Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders](https://www.quantisnow.com/insight/aadi-bioscience-announces-approval-of-all-proposals-at-special-meeting-5919152)
- 2025-02-24 16:38 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Aadi Bioscience Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-aadi-bioscience-inc-5904787)
- 2025-02-24 13:00 UTC [Conference Announcement] [Aadi Bioscience to Present at the TD Cowen 45th Annual Healthcare Conference](https://www.quantisnow.com/insight/aadi-bioscience-to-present-at-the-td-cowen-45th-annual-5904438)
- 2025-02-19 22:08 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Aadi Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-aadi-bioscience-inc-5897668)
- 2025-02-18 21:58 UTC [SEC Form 3] [SEC Form 3 filed by new insider Dornan David](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-dornan-david-5894643)
- 2025-02-18 21:22 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Aadi Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-aadi-bioscience-inc-5894168)
- 2025-02-18 13:00 UTC [Public Offering] [Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer](https://www.quantisnow.com/insight/aadi-bioscience-appoints-david-dornan-phd-as-chief-scientific-officer-5892962)
- 2025-02-14 21:59 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Aadi Bioscience Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-aadi-bioscience-inc-5891510)
- 2025-02-14 19:00 UTC [SEC Form SCHEDULE 13G filed by Aadi Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-aadi-bioscience-inc-5889935)
- 2025-02-05 21:49 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Aadi Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-aadi-bioscience-inc-5873519)
- 2025-02-05 21:05 UTC [Public Offering] [Aadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025](https://www.quantisnow.com/insight/aadi-bioscience-filed-definitive-proxy-statement-and-schedules-special-meeting-5872843)
- 2025-02-04 16:11 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Aadi Bioscience Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-aadi-bioscience-inc-5869312)
- 2025-01-31 22:09 UTC [SEC Form DEFM14A] [SEC Form DEFM14A filed by Aadi Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-defm14a-filed-by-aadi-bioscience-inc-5865738)
- 2025-01-30 20:32 UTC [SEC Form SCHEDULE 13D filed by Aadi Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13d-filed-by-aadi-bioscience-inc-5863234)
- 2025-01-21 21:54 UTC [SEC Form PREM14A filed by Aadi Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-prem14a-filed-by-aadi-bioscience-inc-5852346)
- 2024-12-31 16:13 UTC [SEC Form SCHEDULE 13D filed by Aadi Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13d-filed-by-aadi-bioscience-inc-5827627)
- 2024-12-30 22:04 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Aadi Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-aadi-bioscience-inc-5827141)
- 2024-12-23 22:36 UTC [SEC Form 4] [SEC Form 4 filed by Director Zhao Baiteng](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-zhao-baiteng-5824302)
- 2024-12-23 22:34 UTC [SEC Form 3] [SEC Form 3 filed by new insider Zhao Baiteng](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-zhao-baiteng-5824300)
- 2024-12-20 11:08 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Aadi Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-aadi-bioscience-inc-5821290)
- 2024-12-20 11:05 UTC [SEC Form 8-K] [Aadi Bioscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure](https://www.quantisnow.com/insight/aadi-bioscience-inc-filed-sec-form-8-k-entry-into-a-5821281)
- 2024-12-19 23:30 UTC [Public Offering] [Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing](https://www.quantisnow.com/insight/aadi-bioscience-transforms-with-in-licensing-of-novel-adc-portfolio-100-5821088)
- 2024-11-06 21:08 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Aadi Bioscience Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-aadi-bioscience-inc-5755612)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AADI
- Earnings history: https://www.quantisnow.com/earnings/AADI
- Dividend history: https://www.quantisnow.com/dividends/AADI
- Insider transactions: https://www.quantisnow.com/insiders/AADI
- Options chain: https://www.quantisnow.com/options/AADI
- SEC 8-K filings only: https://www.quantisnow.com/company/AADI/8-k
- RSS and alerts for AADI: https://www.quantisnow.com/docs/rss-feeds.md
